Estimating the Disease Burden of Chronic Inflammatory Demyelinating Polyneuropathy Patients Expressing ANTI-Myelin Associated Glycoprotein in EU5 and USA
Author(s)
Ibrahim R1, Higgins G2
1Evaluate Ltd, London, UK, 2Evaluate Ltd, Maidenhead, WBK, UK
OBJECTIVES : Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare neurological disorder, characterised by progressive weakness and impaired sensory function in the legs and arms. Majority of CIDP patients respond to typical treatment such as plasmapheresis (plasma exchange) and intravenous immunoglobulin(IvIG), however, CIDP patients that produce antibodies against myelin associated glycoprotein (anti-MAG) have low responsive rate to current therapies. The lack of treatment for these patient population negatively impacts their quality of life and strongly demonstrates the need to develop a more targeted therapy against anti-MAG. The aim is to estimate the disease burden of CIDP patients expressing anti-MAG antibodies in USA, United Kingdom, Germany, France, Italy and, Spain(EU5). METHODS : Prevalence of CIDP was modelled, broken down by 5-year age cohorts using scientific literature. The proportion of CIDP patients that express anti-MAG antibodies was estimated using scientific literature. Meta-analysis was carried for USA and EU5, to compare and contrast the data between countries, ensuring diagnostic criteria and inclusion criteria was consistent between all countries. RESULTS : The overall burden of CIDP in USA and EU5 is around 55 thousand patients. The prevalence of CIDP is higher in males compared to females, which is uncommon for an autoimmune disease. Approximately, 5% of these patients produce anti-MAG antibodies in USA and EU5. CONCLUSIONS : The estimated patient population for patients expressing anti-MAG is around 3 thousand in USA and EU5. The prevalence of anti-MAG in CIDP patients is projected to increase in the future, as the diagnostic tools to detect this antibody improves. This also highlights the need to clearly distinct these CIDP patient population (those expressing anti-MAG and those that do not), so they can benefit from early initiation of immunomodulatory treatment, consequently, improving quality of life and survival rate.
Conference/Value in Health Info
2020-11, ISPOR Europe 2020, Milan, Italy
Value in Health, Volume 23, Issue S2 (December 2020)
Code
PND68
Topic
Epidemiology & Public Health
Disease
Neurological Disorders, Rare and Orphan Diseases